Inflammation, Amyloid, and Atrophy in the Aging Brain: Relationships with Longitudinal Changes in Cognition

Journal of Alzheimer's Disease

Volumn 58, Issue 3, 2017, Pages 829-840

  Sala Llonch, Roser ^a,b   Idland, Ane Victoria ^a,c   Borza, Tom ^c,d   Watne, Leiv Otto ^a,c   Wyller, Torgeir Bruun ^c,e   Brækhus, Anne ^e,f   Zetterberg, Henrik ^g,h,i   Blennow, Kaj ^g,h   Walhovd, Kristine Beate ^a   Fjell, Anders Martin ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF OSLO   (Norway)

^d INNLANDET HOSPITAL TRUST   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f VESTFOLD HOSPITAL TRUST   (Norway)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aging; biomarkers; cerebrospinal fluid; cognition; cortical thickness; inflammation; memory; MRI; YKL 40

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CHITINASE 3 LIKE PROTEIN 1; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

AGED; AGING; ARTICLE; BIOACCUMULATION; BRAIN ATROPHY; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLOCK DRAWING TEST; COGNITION; COGNITION ASSESSMENT; COGNITIVE DEFECT; CORTICAL THICKNESS (BRAIN); DISEASE ASSOCIATION; FEMALE; HUMAN; KENDRICK OBJECT LEARNING TEST; LEARNING TEST; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR CORTEX; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREMOTOR CORTEX; PRIORITY JOURNAL; TRAIL MAKING TEST; WORD LIST RECALL; ATROPHY; BRAIN; DIAGNOSTIC IMAGING; INFLAMMATION; METABOLISM; NEUROPSYCHOLOGICAL TEST; ORGAN SIZE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; ATROPHY; BIOMARKERS; BRAIN; CHITINASE-3-LIKE PROTEIN 1; COGNITION; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE; PEPTIDE FRAGMENTS;

EID: 85020440451     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-161146     Document Type: Article

References (55)

1. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
2. Mormino EC (2014) The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations. Neuropsychol Rev 24, 300-312.
3. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 36, 297-309.
4. Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BNM, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD (2016) Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain 139(Pt 9), 2528-2539.
5. Fleischman DA, Arfanakis K, Kelly JF, Rajendran N, Buchman AS, Morris MC, Barnes LL, Bennett DA (2010) Regional brain cortical thinning and systemic inflammation in older persons without dementia. J Am Geriatr Soc 58, 1823-1825.
6. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14, 388-405.
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
8. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT (2008) Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 5, 37.
9. Costello DA, Keenan K, McManus RM, Falvey A, Lynch MA (2016) The age-related neuroinflammatory environment promotes macrophage activation, which negatively impacts synaptic function. Neurobiol Aging 43, 140-148.
10. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM (2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912.
11. Rosén C, Andersson C-H, Andreasson U, Molinuevo JL, Bjerke M, Rami L, Lladó A, Blennow K, Zetterberg H (2014) Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 4, 297-304.
12. Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL (2014) Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis 42, 901-908.
13. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Ann Clin Transl Neurol 3, 12-20.
14. Alcolea D, Vilaplana E, Pegueroles J, Montal V, Sánchez-Juan P, González-Suárez A, Pozueta A, Rodríguez-Rodríguez E, Bartrés-Faz D, Vidal-Piñeiro D, González-Ortiz S, Medrano S, Carmona-Iragui M, Sánchez-Saudinós M, Sala I, Anton-Aguirre S, Sampedro F, Morenas-Rodríguez E, Clarimón J, Blesa R, Lleó A, Fortea J (2015) Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiol Aging 36, 2018-2023.
15. Gispert JD, Monté GC, Falcon C, Tucholka A, Rojas S, Sánchez-Valle R, Antonell A, Lladó A, Rami L, Molinuevo JL (2016) CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging 38, 47-55.
16. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: Asystematic reviewand meta-analysis. Lancet Neurol 15, 673-684.
17. Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P (2015) Neurogranin and YKL-40: Independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther 7, 74.
18. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson J-E, Johansson J-O, Olsson B, Wallin A, Svensson J, Blennow K, Zetterberg H (2011) Cerebrospinal fluid microglial markers in Alzheimer's disease: Elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 13, 151-159.
19. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65, 176-183.
20. Schott JM, Bartlett JW, Fox NC, Barnes J, Alzheimer's Disease Neuroimaging Initiative Investigators (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 68, 825-834.
21. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW (2010) Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study. Neurobiol Aging 31, 1340-1354.
22. Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC (2010) Larger temporal volume in elderly with high versus low betaamyloid deposition. Brain 133, 3349-3358.
23. Fortea J, Sala-Llonch R, Bartrés-Faz D, Lladó A, Solé-Padullés C, Bosch B, Antonell A, Olives J, Sanchez-Valle R, Molinuevo JL, Rami L (2011) Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol Psychiatry 70, 183-190.
24. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA (2011) Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 69, 1032-1042.
25. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM, Alzheimer's Disease Neuroimaging Initiative (2010) Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex 20, 2069-2079.
26. Hedden T, Oh H, Younger AP, Patel TA (2013) Metaanalysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80, 1341-1348.
27. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165.
28. Spreen O, Strauss E (1991) A compendium of neuropsychological tests: Administration, norms, and commentary, Oxford University Press, New York.
29. Reitan RM (1955) The relation of the trail making test to organic brain damage. J Consult Psychol 19, 393-394.
30. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
31. Shulman KI (2000) Clock-drawing: Is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15, 548-561.
32. Kendrick DC, Gibson AJ, Moyes IC (1979) The revised kendrick battery: Clinical studies. Br J Soc Clin Psychol 18, 329-340.
33. Dale AM, Fischl B, Sereno MI (1999) Cortical surfacebased analysis. I. Segmentation and surface reconstruction. Neuroimage 9, 179-194.
34. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341-355.
35. Jovicich J, Marizzoni M, Sala-Llonch R, Bosch B, Bartrés-Faz D, Arnold J, Benninghoff J, Wiltfang J, Roccatagliata L, Nobili F, Hensch T, Tränkner A, Schönknecht P, Leroy M, Lopes R, Bordet R, Chanoine V, Ranjeva J-P, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Blin O, Frisoni GB (2013) Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. Neuroimage 83, 472-484.
36. Reuter M, Schmansky NJ, Rosas HD, Fischl B (2012) Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 61, 1402-1418.
37. Reuter M, Fischl B (2011) Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage 57, 19-21.
38. Smith EE, Salat DH, Jeng J, McCreary CR, Fischl B, Schmahmann JD, Dickerson BC, Viswanathan A, Albert MS, Blacker D, Greenberg SM (2011) Correlations between MRIwhite matter lesion location and executive function and episodic memory. Neurology 76, 1492-1499.
39. Olsson E, Klasson N, Berge J, Eckerström C, Edman A, Malmgren H, Wallin A, Malmgren H, Wallin A (2013) White matter lesion assessment in patients with cognitive impairment and healthy controls: Reliability comparisons between visual rating, a manual, and an automatic volumetrical MRI method-the Gothenburg MCI study. J Aging Res 2013, 198471.
40. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
41. Niemantsverdriet E, Goossens J, Struyfs H, Martin J-J, Goeman J, De Deyn PP, Vanderstichele H, Engelborghs S (2016) Diagnostic impact of cerebrospinal fluid biomarker (pre-)analytical variability in Alzheimer's disease. J Alzheimers Dis 51, 97-106.
42. Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, Herukka S-K, Soininen H, Law I, Bahl JMC, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BNM, Visser PJ (2016) Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. Neurology 86, 50-58.
43. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289.
44. Hagler DJ, Saygin AP, Sereno MI (2006) Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. Neuroimage 33, 1093-1103.
45. Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, Storandt M, Morris JC (2005) Predictors of preclinical Alzheimer disease and dementia: A clinicopathologic study. Arch Neurol 62, 758-765.
46. Damoiseaux JS, Beckmann CF, Arigita EJ, Barkhof F, Scheltens P, Stam CJ, Smith SM, Rombouts SA (2008) Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex 18, 1856-1864.
47. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB (2014) What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol 117, 20-40.
48. Braak H, Braak E (1997) Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 18, 351-357.
49. Aschenbrenner AJ, Balota DA, Fagan AM, Duchek JM, Benzinger TLS, Morris JC (2015) Alzheimer disease cerebrospinal fluid biomarkers moderate baseline differences and predict longitudinal change in attentional control and episodic memory composites in the Adult Children Study. J Int Neuropsychol Soc 21, 573-583.
50. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB (2013) Brain changes in older adults at very low risk for Alzheimer's disease. J Neurosci 33, 8237-8242.
51. Persson N, Ghisletta P, Dahle CL, Bender AR, Yang Y, Yuan P, Daugherty AM, Raz N (2016) Regional brain shrinkage and change in cognitive performance over two years: The bidirectional influences of the brain and cognitive reserve factors. Neuroimage 126, 15-26.
52. Rodrigue KM, Raz N (2004) Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. J Neurosci 24, 956-963.
53. Melah KE, Lu SY-F, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB (2015) Cerebrospinal fluid markers of Alzheimer's disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer's disease. J Alzheimers Dis 50, 873-886.
54. Arenaza-Urquijo EM, Molinuevo J-L, Sala-Llonch R, Solé-Padullés C, Balasa M, Bosch B, Olives J, Antonell A, Lladó A, Sánchez-Valle R, Rami L, Bartrés-Faz D (2013) Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels. J Alzheimers Dis 35, 715-726.
55. Gouwens LK, Makoni NJ, Rogers VA, Nichols MR (2016) Amyloid-β 42 protofibrils are internalized by microglia more extensively than monomers. Brain Res 1648, 485-495.